BeiGene의 PD-1 억제제 티슬렐리주맙, 일본 승인 획득…글로벌 제약 공룡에 도전장
BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
BeiGene received regulatory approval from Japan's MHLW for its PD-1 inhibitor tislelizumab to treat non-small cell lung cancer, marking its entry into the Japanese market.
百济神州的抗 PD-1 抗体替雷利珠单抗获得日本厚生劳动省批准，用于治疗非小细胞肺癌。
BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
Where this signal fits in the broader landscape.
BeiGene, 2025년 4분기 및 연간 재무 실적 발표
BeOne Medicines, 2025년 4분기 및 회계연도 재무 실적 발표
BeOne Medicines, 2025년 4분기 및 연간 재무 실적 발표 예정
BeiGene의 Sonrotoclax, 재발성 또는 불응성 맨틀세포 림프종(R/R MCL) 치료제로 세계 최초 승인 획득
Sonrotoclax, R/R MCL 및 R/R CLL/SLL 치료에 세계 최초 승인 획득
https://pj.jiho.jp/article/253329
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
로그인